Nurexone Biologic Inc (NRXBF) Finansal

NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The company is headquartered in Haifa, Haifa. The company went IPO on 2012-05-08. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.